Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation

International Journal of Cancer

Volumn 122, Issue 1, 2008, Pages 63-70

  Ahmed, Mansoor M ^a,b   Sheldon, David ^c   Fruitwala, Mushtaq A ^d,f   Venkatasubbarao, Kolaparthi ^d,g   Lee, Eun Y ^e   Gupta, Seema ^a   Wood, Craig ^c   Mohiuddin, Mohammed ^b   Strodel, William E ^c  

^a WEIS CENTER FOR RESEARCH   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f Perrigo   (United States)

^g Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

K ras mutation; Pancreatic cancer; PAR 4; Survival

Indexed keywords

MESSENGER RNA; OLIGONUCLEOTIDE; PROTEINASE ACTIVATED RECEPTOR 4;

ALLELE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DNA HYBRIDIZATION; DOWN REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; RECEPTORS, THROMBIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 36749017447     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23019     Document Type: Article

References (33)

1. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
2. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995;80:279-84.
3. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993;75:653-60.
4. Wang L, Miura M, Bergeron L, Zhu H, Yuan J. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994;78:739-50.
5. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005;65:8433-41.
6. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways [see comments]. Nature 1993;362:849-52.
7. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
8. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, Yanagisawa A, Tsuchiya E, Kato Y, Nakamura Y. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992;52:6696-8.
9. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
10. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3.
11. Shibata D, Capella G, Perucho M. Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Baillieres Clin Gastroenterol 1990;4:151-69.
12. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
13. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
14. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC, Lane DP, Lemoine NR. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
15. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
16. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
17. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 1998;58:1754-61.
18. Zhao J, Buick RN. Regulation of transforming growth factor beta receptors in H-ras oncogene-transformed rat intestinal epithelial cells. Cancer Res 1995;55:6181-8.
19. Venkatasubbarao K, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower WR, Jr, Salhab KF, McGrath P, Strodel W, Freeman JW. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res 2000;20:43-51.
20. Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J 1999;18:6362-9.
21. Sells SF, Wood DP, Jr, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994;5:457-66.
22. Rangnekar VM. Apoptosis mediated by a novel leucine zipper protein Par-4. Apoptosis 1998;3:61-6.
23. Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 1999;274:29976-83.
24. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996;86:777-86.
25. Lee JH, Lee SK, Yang MH, Ahmed MM, Mohiuddin M, Lee EY. Expression and mutation of H-ras in uterine cervical cancer. Gynecol Oncol 1996;62:49-54.
26. Mansoor AM, Bharadwaj TP, Sethuraman S, Chandy M, Pushpa V, Kamada N, Murthy PB. Analysis of karyotype. SCE, and point mutation of. RAS oncogene in Indian MDS patients. Cancer Genet Cytogenet 1993;65:12-20.
27. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996;16:6945-56.
28. Das A, Chendil D, Dey S, Mohiuddin M, Milbrandt JD, Rangnekar VM, Ahmed MM. Ionizing radiation downregulates p53 protein in primary Egr-1-/- mouse embryonic fibroblast cells causing enhanced resistance to apoptosis. J Biol Chem 2001;276:3279-86.
29. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS, Jr. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997;272:24113-6.
30. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997;22:355-8.
31. Galang CK, Der CJ, Hauser CA. Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. Oncogene 1994;9:2913-21.
32. Saha D, Datta PK, Beauchamp RD. Oncogenic Ras represses TGF-beta/SMAD signaling by degrading tumor suppressor Smad4. J Biol Chem 2001;22:22.
33. Pruitt K, Ulku AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-70.